Literature DB >> 29032733

CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.

Jun Liu1, Xi Zhang1, Jiang F Zhong2, Cheng Zhang1.   

Abstract

Relapsed/refractory acute lymphoblastic leukemia (ALL) has a low remission rate after chemotherapy, a high relapse rate and poor long-term survival even when allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed. Chimeric antigen receptors redirected T cells (CAR-T cells) can enhance disease remission with a favorable outcome for relapsed/refractory ALL, though some cases quickly relapsed after CAR-T cell treatment. Thus, treatment with CAR-T cells followed by allo-HSCT may be the best way to treat relapsed/refractory ALL. In this review, we first discuss the different types of CAR-T cells. We then discuss the treatment of relapsed/refractory ALL using only CAR-T cells. Finally, we discuss the use of CAR-T cells, followed by allo-HSCT, for the treatment of relapsed/refractory ALL.

Entities:  

Keywords:  B-cell acute lymphoblastic leukemia; CAR-T cells; allogeneic hematopoietic stem cell transplantation; relapsed/refractory

Mesh：

Substances：

Year:  2017        PMID： 29032733     DOI： 10.2217/imt-2017-0072

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  11 in total

1.  Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.

Authors:  Linhui Hu; Alice Charwudzi; Qian Li; Weiwei Zhu; Qianshan Tao; Shudao Xiong; Zhimin Zhai
Journal:  Ann Hematol       Date:  2021-02-15       Impact factor: 3.673

Review 2.  Microbial L-asparaginase as a promising enzyme for treatment of various cancers.

Authors:  Farshad Darvishi; Zohreh Jahanafrooz; Ahad Mokhtarzadeh
Journal:  Appl Microbiol Biotechnol       Date:  2022-07-25       Impact factor: 5.560

Review 3.  Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.

Authors:  Md Mominur Rahman; Tapan Behl; Md Rezaul Islam; Md Noor Alam; Md Mohaimenul Islam; Ali Albarrati; Mohammed Albratty; Abdulkarim M Meraya; Simona Gabriela Bungau
Journal:  Molecules       Date:  2022-06-13       Impact factor: 4.927

4.  Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.

Authors:  Cheng Zhang; Jiaping He; Li Liu; Jishi Wang; Sanbin Wang; Ligen Liu; Jian Ge; Lei Gao; Li Gao; Peiyan Kong; Yao Liu; Jia Liu; Yu Han; Yongliang Zhang; Zhe Sun; Xun Ye; Wenjie Yin; Martina Sersch; Lianjun Shen; Wei William Cao; Xi Zhang
Journal:  Blood Cancer J       Date:  2022-06-24       Impact factor: 9.812

5.  Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant.

Authors:  Qing Li; Juan Mu; Jijun Yuan; Zhenxing Yang; Jia Wang; Qi Deng
Journal:  Onco Targets Ther       Date:  2020-11-09       Impact factor: 4.147

6.  Identification of leukemia stem cell expression signatures through Monte Carlo feature selection strategy and support vector machine.

Authors:  JiaRui Li; Lin Lu; Yu-Hang Zhang; YaoChen Xu; Min Liu; KaiYan Feng; Lei Chen; XiangYin Kong; Tao Huang; Yu-Dong Cai
Journal:  Cancer Gene Ther       Date:  2019-05-29       Impact factor: 5.987

Review 7.  Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.

Authors:  Allison Barz Leahy; Caitlin W Elgarten; Stephan A Grupp; Shannon L Maude; David T Teachey
Journal:  Expert Rev Anticancer Ther       Date:  2018-10       Impact factor: 3.627

Review 8.  Genetically enhanced T lymphocytes and the intensive care unit.

Authors:  Tiberiu Tat; Huming Li; Catalin-Sorin Constantinescu; Anca Onaciu; Sergiu Chira; Ciprian Osan; Sergiu Pasca; Bobe Petrushev; Vlad Moisoiu; Wilhelm-Thomas Micu; Cristian Berce; Sebastian Tranca; Delia Dima; Ioana Berindan-Neagoe; Jianliang Shen; Ciprian Tomuleasa; Liren Qian
Journal:  Oncotarget       Date:  2018-03-27

Review 9.  Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies.

Authors:  Yuru Nie; Weiqing Lu; Daiyu Chen; Huilin Tu; Zhenling Guo; Xuan Zhou; Meifang Li; Sanfang Tu; Yuhua Li
Journal:  Biomark Res       Date:  2020-05-27

10.  CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.

Authors:  Shupeng Wen; Zhiyun Niu; Lina Xing; Ying Wang; Hang Li; Na Kuang; Jianmin Luo; Xuejun Zhang; Fuxu Wang
Journal:  BMC Cancer       Date:  2018-11-20       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.